AGIO vs. SNDX, SDGR, CPRX, GPCR, GERN, NAMS, AMRX, SUPN, AVDL, and HRMY
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Catalyst Pharmaceuticals (CPRX), Structure Therapeutics (GPCR), Geron (GERN), NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Agios Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 2 mentions for Agios Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.66 beat Agios Pharmaceuticals' score of -0.14 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -1,312.64%. Agios Pharmaceuticals' return on equity of -38.08% beat Syndax Pharmaceuticals' return on equity.
Syndax Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Agios Pharmaceuticals received 114 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 67.90% of users gave Agios Pharmaceuticals an outperform vote while only 64.54% of users gave Syndax Pharmaceuticals an outperform vote.
Agios Pharmaceuticals currently has a consensus price target of $33.50, suggesting a potential upside of 2.26%. Syndax Pharmaceuticals has a consensus price target of $34.42, suggesting a potential upside of 61.73%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Summary
Syndax Pharmaceuticals beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
